VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
MHLA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
MHLAMaiden Holdings, Ltd. 6.625 NT 2046
$10.85$1.1B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksMHLAFinancials

Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) Financials

17Y historyFree accessUpdated daily

The company's underwriting profitability remains severely strained, evidenced by a net margin of -356.10% that reflects the overwhelming cost of settling legacy claims.

MHLA Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08
Revenue41.58M56.44M89.23M58.13M98.72M184.12M576.13M2.16B2.14B2.05B2.57B2.38B2.11B1.9B1.64B1.25B983.15M419.77M
Revenue Growth %-57.85%-36.75%53.5%-41.11%-46.38%-68.04%-73.39%1.22%4.24%-20.26%8.06%12.85%11.07%15.81%31.44%26.94%134.21%-
Medical Costs & Claims000000000000005.03M5.81M38.73M1.25M
Medical Cost Ratio %0%0%0%0%0%0%0%0%0%0%0%0%0%0%0.31%0.47%3.94%0.3%
Gross Profit41.58M56.44M89.23M58.13M98.72M184.12M576.13M2.16B2.14B2.05B2.57B2.38B2.11B1.9B1.64B1.24B944.42M418.51M
Gross Margin %100%100%100%100%100%100%100%100%100%100%100%100%100%100%99.69%99.53%96.06%99.7%
Gross Profit Growth %--36.75%53.5%-41.11%-46.38%-68.04%-73.39%1.22%4.24%-20.26%8.06%12.85%11.07%16.16%31.65%31.53%125.66%-
Operating Expenses23.5M35.35M30.8M30.95M36.02M39.12M667.09M2.6B2.27B1.94B2.42B2.22B1.97B1.81M53.89M42.18M-882.02M14.97M
OpEx / Revenue %56.52%62.63%34.51%53.24%36.49%21.25%115.79%119.89%106%94.64%93.96%93.2%93.15%0.1%3.29%3.38%-89.71%3.57%
Depreciation & Amortization-843K02.75M49.32M3.45M6.24M5.91M4.9M5.45M20.3M-147.63M-157.75M-141.72M-87.22M0000
Combined Ratio %56.52%62.63%34.51%53.24%36.49%21.25%115.79%119.89%106%94.64%93.96%93.2%93.15%0.1%3.59%3.85%-85.78%3.87%
Operating Income3.52M21.09M58.44M27.18M62.7M145M-93.67M-429.49M-113.42M96.58M147.63M157.75M141.72M87.22M1.58B1.2B62.4M403.54M
Operating Margin %8.47%37.37%65.49%46.76%63.51%78.75%-16.26%-19.84%-5.3%4.71%5.74%6.62%6.72%4.59%96.41%96.15%6.35%96.13%
Operating Income Growth %--63.91%114.96%-56.64%-56.76%254.8%78.19%-278.69%-217.43%-34.58%-6.41%11.31%62.48%-94.48%31.79%1823.11%-84.54%-
EBITDA-4.41M21.09M61.18M76.5M66.15M151.25M-87.76M-424.59M-107.97M116.88M00001.58B1.2B62.4M403.54M
EBITDA Margin %-10.62%37.37%68.56%131.6%67.01%82.15%-15.23%-19.61%-5.05%5.7%0%0%0%0%96.41%96.15%6.35%96.13%
Interest Expense19.27M19.27M00019.32M0000000034.16M36.47M34.43B0
Non-Operating Income212.35M201.74M-58.44M-27.18M-62.7M-145M-528.92M-2.11B-2.09B-2B-2.51B-2.32B-2.05B01.52B1.09B00
Pretax Income-210.02M-199.91M-38.37M-60.6M26.66M41.66M-110.27M-449.85M-154.41M79.47M126.32M103.7M104.72M52.47M30.45M71.19M62.4M18.79M
Pretax Margin %-505.08%-354.23%-43%-104.24%27.01%22.63%-19.14%-20.78%-7.22%3.87%4.91%4.35%4.96%2.76%1.86%5.7%6.35%4.48%
Income Tax1.06M1.05M196K-557K15K-104K-911K441K-6.76M413K2.04M2.16M1.86M2.21M1.93M1.33M1.34M0
Effective Tax Rate %-0.5%-0.53%-0.51%0.92%0.06%-0.25%0.83%-0.1%4.38%0.52%1.61%2.09%1.78%4.22%6.33%1.87%2.15%0%
Net Income-211.06M-200.97M-38.57M-60.04M26.64M41.76M-109.36M-476.16M-176.98M46.14M100.09M76.96M87.78M46.51M28.52M69.87M61.06M18.79M
Net Margin %-507.58%-356.1%-43.22%-103.28%26.99%22.68%-18.98%-22%-8.27%2.25%3.89%3.23%4.16%2.45%1.74%5.6%6.21%4.48%
Net Income Growth %-718.08%-421.06%35.76%-325.34%-36.2%138.19%77.03%-169.05%-483.58%-53.9%30.05%-12.33%88.74%63.06%-59.17%14.43%224.88%-
EPS (Diluted)-2.13-2.01-0.380.631.350.93-1.32-5.73-2.070.591.171.041.150.640.390.980.870.32
EPS Growth %57.72%-428.95%-160.32%-53.33%45.16%170.45%76.96%-176.81%-450.85%-49.57%12.5%-9.57%79.69%64.1%-60.2%12.64%171.88%-
EPS (Basic)--2.01-0.380.631.350.93-1.32-5.74-2.070.581.311.041.180.640.400.990.880.32
Diluted Shares Outstanding99.12M99.9M101.38M87.11M86.07M84.33M83.06M83.05M85.68M78.69M85.64M74.12M76.42M73.11M72.9M71.37M70.06M59.34M

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Legacy reserve development volatility

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2025Q1)

Revenue Contraction Reflects Strategic Run-off

As reported in recent financial filings, MHLA experienced a significant revenue decline of 51.4% in 2025Q1, signaling a rapid contraction of the active underwriting book that suggests the company is effectively transitioning toward a run-off state rather than pursuing growth in its diversified reinsurance segment.

The persistent volatility in top-line figures, including the extreme -129.5% revenue growth observed in 2024Q4, indicates that the firm is likely navigating the impact of treaty commutations and the deliberate shedding of legacy business. Investors should monitor whether the remaining revenue base can sustain the fixed costs associated with maintaining a Bermuda-based insurance platform.

Underwriting Profitability Remains Severely Strained

Based on the provided income statement data, the company's net margin of -356.10% highlights a profound inability to generate underwriting profit, as the costs of settling legacy claims appear to be consistently overwhelming the premiums earned from the shrinking portfolio of active reinsurance contracts.

The absence of consistent positive net income, punctuated by a $158.0 million loss in 2024Q4, suggests that the firm's operational structure is currently incapable of achieving a sustainable combined ratio. This performance implies that the company is effectively consuming its capital base to satisfy historical liabilities rather than creating value through new underwriting.

Legacy Liabilities Masking Operational Viability

According to the historical income statement trends, the recurring net losses suggest that prior-year reserve development remains a significant headwind, potentially masking the underlying performance of the diversified segment and complicating any assessment of the company's true long-term solvency or its ability to settle future claims.

The lack of transparency regarding specific loss ratios in the provided data warrants further investigation into whether the company is facing adverse development on its long-tail workers' compensation and general liability lines. Such uncertainty implies that the current equity base may be subject to further erosion if reserve adequacy is not maintained.

Distressed Valuation Reflects Liquidation Risk

As indicated by the company's recent financial performance, the market appears to be pricing MHLA as a liquidating entity, with the -356.10% net margin suggesting that the firm's primary value may reside in its remaining insurance licenses rather than its capacity to generate future underwriting income.

The extreme volatility in quarterly earnings, including the $36.0 million profit in 2022Q4 followed by subsequent losses, suggests that the company's financial results are heavily influenced by non-recurring accounting adjustments and commutations. Investors should be cautious of the potential for further capital impairment as the firm continues to navigate its legacy run-off.

MHLA — Frequently Asked Questions

Quick answers to the most common questions about buying MHLA stock.

What was Maiden Holdings, Ltd. 6.625 NT 2046's (MHLA) revenue in 2024?

For fiscal year 2024, Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) reported total revenue of $56.4M. This represents a 86.6% decline compared to $419.8M in 2008.

Is Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) profitable?

Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) reported a net loss of $201.0M for the fiscal year ending 2024.

What is Maiden Holdings, Ltd. 6.625 NT 2046's operating profit margin?

Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) reported an operating income of $21.1M, resulting in an operating profit margin of 37.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Maiden Holdings, Ltd. 6.625 NT 2046's gross profit and gross margin?

Maiden Holdings, Ltd. 6.625 NT 2046 (MHLA) generated $56.4M in gross profit for the year, representing a gross profit margin of 100.0%. This demonstrates the company's core pricing power and production efficiency.